ClinicalTrials.gg
Active, not recruitingNCT06254482Updated Nov 21, 2025

An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)

A Phase 2 interventional study of Votoplam in Huntington Disease, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 24 sites in 10 countries. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Aug 2023, registered Feb 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
25 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Huntington Disease with a site in Germany — 7 open to participants now, 9 under way, 3 of them phase 3. Huntington Disease · Germany.

Enrollment
15th of 37
144 · median 95
Started
2023
with 2 others
Phase 2
16 of 44
none open now
Registered
39th of 44
by date
Lead sponsor
5 of 44
Novartis Pharmaceuticals

Among the 44 studies in Huntington Disease with a site in Germany, this one is the 15th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2023, is one of 16 in phase 2, and was the 39th registered.

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

Browse Huntington Disease studies →

Open to participants now

7 of the 44 studies in Huntington Disease with a site in Germany are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.

This study: 25 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Huntington Disease with a site in Germany, or all of them as a file.
02

Study summary

The primary goal of this study is to evaluate the long-term safety and pharmacodynamic effects of votoplam in participants with HD.

Read the detailed description

Participants who completed the Treatment Period in the parent Phase 2a Study PTC518-CNS-002-HD (NCT05358717), fulfilled the enrollment criteria, and chose to enroll in this extension study will undergo baseline evaluations and be assessed for 54 additional months.

All participants will receive active votoplam in this extension study. Participants who received votoplam in the parent Study PTC518-CNS-002-HD will continue at the same dose level they received in that study in a blinded fashion (5, 10 milligrams [mg]). Participants who received placebo in the parent Study PTC518-CNS-002-HD will be allocated to a votoplam dose level according to the same dosing group in which they were previously randomized (5, 10 mg).

03

Conditions studied

  • Huntington Disease

Keywords

  • Neurodegenerative disorder
  • Rare disease
04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant who has completed the Treatment Period in Study PTC518-CNS-002-HD.

Exclusion criteria

Exclusion Criteria:

  • Participants who have not previously completed the Treatment Period in Study PTC518-CNS-002-HD.

Note: Other inclusion and exclusion criteria may apply.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    Votoplam 5 mg

    Participants will receive Votoplam 5 mg tablets once daily orally for 48 months.

    Drug: Votoplam

  • Experimental
    Votoplam 10 mg

    Participants will receive votoplam 10 mg tablets once daily orally for 48 months.

    Drug: Votoplam

Interventions

  • Votoplam will be administered per dose and schedule specified in the arm.

    Also known as: HTT227 / PTC518

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Baseline up to Month 54

  2. Blood Total Huntingtin Protein (tHTT) Levels

    Time frame: Baseline up to Month 52

Secondary outcomes

  1. Change From Baseline in Caudate Volume as Assessed Via Volumetric Magnetic Resonance Imaging (vMRI) at Month 48

    Time frame: Baseline, Month 48

  2. Change From Baseline in Composite Unified Huntington's Disease Rating Scale (cUHDRS) Scores at Month 48

    Time frame: Baseline, Month 48

  3. Cerebrospinal Fluid (CSF) Mutant Huntingtin Protein (mHTT) Levels

    Time frame: Baseline up to Month 48

  4. Blood mHTT Protein Levels

    Time frame: Baseline up to Month 52

07

Study locations

24 sites
  • Novartis Investigative Site
    Clayton, 3168, Australia
  • Novartis Investigative Site
    Westmead, 2145, Australia
  • Novartis Investigative Site
    Innsbruck, 6020, Austria
  • Novartis Investigative Site
    Ottawa, K1Y 4E9, Canada
  • Novartis Investigative Site
    Angers, 49100, France
  • Novartis Investigative Site
    Marseille, 13385, France
  • Novartis Investigative Site
    Paris, 75013, France
  • Novartis Investigative Site
    Berlin, 10117, Germany
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Münster, 48149, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Bologna, 40139, Italy
  • Novartis Investigative Site
    Milan, 20133, Italy
  • Novartis Investigative Site
    San Giovanni Rotondo, 71013, Italy
  • Novartis Investigative Site
    Leiden, 2333 ZA, Netherlands
  • Novartis Investigative Site
    Christchurch, 8011, New Zealand
  • Novartis Investigative Site
    Barakaldo, 48903, Spain
  • Novartis Investigative Site
    Barcelona, 8025, Spain
  • Novartis Investigative Site
    Burgos, 90550, Spain
  • Novartis Investigative Site
    Madrid, 28034, Spain
  • Novartis Investigative Site
    Birmingham, B15 2FG, United Kingdom
  • Novartis Investigative Site
    Cardiff, CF14 4XW, United Kingdom
  • Novartis Investigative Site
    London, WC1N 3BG, United Kingdom
  • Novartis Investigative Site
    Manchester, M13 9WL, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Jul 2029, 70 months after the start.

Of 22 phase 2 interventional studies under Huntington Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's planned 70 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2024
First posted
Feb 12, 2024
StartActual
Aug 25, 2023
Primary completionEst.
Jul 16, 2029
CompletionEst.
Jul 16, 2029
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06254482
Responsible party
Sponsor
First posted
Feb 12, 2024
Start date
Aug 25, 2023
Primary completion
Jul 16, 2029 (estimated)
Completion
Jul 16, 2029 (estimated)
Last update
Nov 21, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Votoplam

Start the discussion